Literature DB >> 3208795

On the pharmacokinetics and metabolism of propiverine in man.

K O Haustein1, G Hüller.   

Abstract

The pharmacokinetics of 14C-propiverine was studied in 13 volunteers and in 2 patients after a single i.v. injection of 5 mg or after oral administration of 15 mg. To each dose 1.11 MBq 14C-propiverine was added. The radioactivity measured in plasma, urine (and bile fluid), and the metabolites were estimated by an extraction procedure together with TLC and radiochromatography. Propiverine was eliminated from the plasma with a half-life time (t0.5) of 4.1 h (i.v. and per os), while the plasma radioactivity decreased with a t0.5 of 21.2 (i.v.) or 10.4 h (per os). Within 4 days, 84.5 (i.v.) or 53.5% (per os) of the administered radioactivity was excreted in urine. The absorption of radioactivity of propiverine amounted to 84.5%, while the amount of available propiverine was only 48.9%. In two patients with cannulated ductus choledochus, 21.5 or 14.7% of the administered radioactivity was excreted within 2 days. The metabolic pattern of plasma, urine and bile fluid mainly consisted of amine oxides, substances oxidized in the propyl side chain, desalkylated metabolites, substances with a N-demethylated piperidino group or with ester cleavage, and glucuronide conjugates. Unchanged propiverine appeared in plasma, urine and bile at about 6 to 8% of the administered dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208795     DOI: 10.1007/BF03191308

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  1 in total

1.  Studies on the metabolic pattern of propiverine in urine after single administration.

Authors:  G Hüller; K O Haustein; S Scheithauer
Journal:  Pharmazie       Date:  1988-02       Impact factor: 1.267

  1 in total
  11 in total

Review 1.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

Authors:  Martin C Michel; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11       Impact factor: 3.000

Review 2.  Urothelial effects of oral agents for overactive bladder.

Authors:  Karl-Erik Andersson; Claudius Fullhase; Roberto Soler
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

3.  Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.

Authors:  Werner Siegmund; Ulla Sillén; Göran Läckgren; Frieder Schnabel; Gerd Mürtz; Cornelia Feustel
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

4.  Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction.

Authors:  Melinda Wuest; Anke Weiss; Magali Waelbroeck; Manfred Braeter; Lutz-Ullrich Kelly; Oliver W Hakenberg; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-20       Impact factor: 3.000

5.  Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.

Authors:  C Müller; W Siegmund; R Huupponen; T Kaila; G Franke; E Iisalo; M Zschiesche
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

6.  Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction.

Authors:  Melinda Wuest; Juliane Hecht; Torsten Christ; Manfred Braeter; Christian Schoeberl; Oliver W Hakenberg; Manfred P Wirth; Ursula Ravens
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

7.  Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.

Authors:  Karen May; Thomas Giessmann; Danilo Wegner; Reinhard Oertel; Christiane Modess; Stefan Oswald; Manfred Braeter; Werner Siegmund
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

Review 8.  Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.

Authors:  Kate McKeage
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

9.  Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.

Authors:  Hai-Lei Zhu; Keith L Brain; Manami Aishima; Atsushi Shibata; John S Young; Katsuo Sueishi; Noriyoshi Teramoto
Journal:  J Pharmacol Exp Ther       Date:  2007-10-10       Impact factor: 4.030

Review 10.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.